Étiquette : essai clinique

Ketamine a Panacea for Resistant Depression? Not So Fast, Experts Say, Nancy A. Melville , April 04, 2019

Ketamine a Panacea for Resistant Depression? Not So Fast, Experts Say Nancy A. Melville April 04, 2019 https://www.medscape.com/viewarticle/911378#vp_3   CHICAGO — Ketamine's rapid antidepressant effects and its recent approval by the US Food and Drug Administration (FDA) has clinicians and patients alike buzzing with excitement. However, for some experts, this excitement only serves to heighten concerns about the many unknowns and potential long-term side effects of the drug, which began its long history as an anesthetic. Here, at the Anxiety and Depression Association of American (ADAA) 2019 Conference, experts debated the drug's merits and potential pitfalls. "These are exciting times and I think ketamine has opened a new era," Carlos [...]

Lire la suite

Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study, Rafael F. Sanchez et al., 2016

Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study. Rafael F. Sanchez, F. de Lima Osorio, R.G. Dos Santos, L.R. Macedo, J.P. Maia-de-Oliveira, L. Wichert-Ana, D.B. de Araujo, J. Riba, J.A. Crippa, J.E. Hallak Journal of Clinical Psychopharmacology, 2016, 36, 1, 77-81. doi: 10.1097/JCP.0000000000000436. PMID : 26650973 Abstract Ayahuasca is an Amazonian botanical hallucinogenic brew which contains dimethyltryptamine, a 5-HT2A receptor agonist, and harmine, a monoamine-oxidase A inhibitor. Our group recently reported that ayahuasca administration was associated with fast-acting antidepressive effects in 6 depressive patients. The objective of the present work was to assess the antidepressive potentials of [...]

Lire la suite

État des lieux de la recherche sur les capacités thérapeutiques des « substances hallucinogènes » au 21e siècle, Christian Sueur, 2017

État des lieux de la recherche sur les capacités thérapeutiques des « substances hallucinogènes » au 21e siècle Christian Sueur Psychotropes, 2017/3 (Vol. 23), p. 125-163. DOI 10.3917/psyt.233.0125 https://www.cairn.info/revue-psychotropes-2017-3-page-125.htm   Résumé : L’utilisation thérapeutique des substances psychédéliques a été concomitante de la découverte du LSD et de la Mescaline après la Seconde Guerre mondiale. Ces utilisations thérapeutiques concernaient, à l’origine, essentiellement « l’accompagnement » des psychothérapies (thérapies psycholytiques), le traitement des addictions (alcool, puis opiacés) et, du fait de leurs capacités anxiolytiques et antidépressives, la prise en charge des troubles psychologiques post-traumatiques, les dépressions résistantes, les pathologies obsessionnelles et psychosomatiques (douleurs, migraines…) et l’accompagnement des fins [...]

Lire la suite

Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol, Douglas L. Boggs et al., 2018

Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol Douglas L. Boggs, Jacques D. Nguyen, Daralyn Morgenson, Michael A. Taffe and Mohini Ranganathan Neuropsychopharmacology. 2018 Jan; 43(1): 142–154. Published online 2017 Oct 18. Prepublished online 2017 Sep 6. doi: 10.1038/npp.2017.209 PMCID: PMC5719112 PMID: 28875990 Abstract The plant Cannabis sativa, commonly called cannabis or marijuana, has been used for its psychotropic and mind-altering side effects for millennia. There has been growing attention in recent years on its potential therapeutic efficacy as municipalities and legislative bodies in the United States, Canada, and other countries grapple with enacting policy to facilitate the use of cannabis or its constituents for [...]

Lire la suite

A protocol for the delivery of cannabidiol (CBD) and combined CBD and ∆9-tetrahydrocannabinol (THC) by vaporisation, Nadia SOLOWIJ et al., 2014,

A protocol for the delivery of cannabidiol (CBD) and combined CBD and ∆9-tetrahydrocannabinol (THC) by vaporisation Nadia SOLOWIJ, Samantha J. BROYD, Hendrika H. Van HELL, Arno HAZEKAMP BMC Pharmacol Toxicol, 2014, 15, 58 Published online 2014 Oct 16. doi: 10.1186/2050-6511-15-58 PMCID: PMC4274767 PMID: 25319497 Abstract Background Significant interest has emerged in the therapeutic and interactive effects of different cannabinoids. Cannabidiol (CBD) has been shown to have anxiolytic and antipsychotic effects with high doses administered orally. We report a series of studies conducted to determine the vaporisation efficiency of high doses of CBD, alone and in combination with ∆9-tetrahydrocannabinol (THC), to achieve faster onset effects in experimental and clinical [...]

Lire la suite

Prospects for the Use of Cannabinoids in Oncology and Palliative Care Practice : A Review of the Evidence, Tomasz Dzierzanowski, 2019.

Prospects for the Use of Cannabinoids in Oncology and Palliative Care Practice: A Review of the Evidence. Tomasz DZIERZANOWSKI Cancers (Basel), 2019, 11, 2 Abstract There is an increased interest in the use of cannabinoids in the treatment of symptoms in cancer and palliative care patients. Their multimodal action, in spite of limited efficacy, may make them an attractive alternative, particularly in patients with multiple concomitant symptoms of mild and moderate intensity. There is evidence to indicate cannabis in the treatment of pain, spasticity, seizures, sleep disorders, nausea and vomiting, and Tourette syndrome. Although the effectiveness of cannabinoids is limited, it was confirmed in [...]

Lire la suite

Cannabidiol as a suggested candidate for treatment of autism spectrum disorder, Shani Poleg et al., 2019

Cannabidiol as a suggested candidate for treatment of autism spectrum disorder. POLEG S., GOLUBCHIK P., OFFEN D., WEIZMAN A. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 8, 89, 90-96. doi: 10.1016/j.pnpbp.2018.08.030 Abstract Autism Spectrum Disorder (ASD) is characterized by persistent deficits in social communication, restricted and repetitive patterns of behavior, interests, or activities and often intellectual disabilities. ASD has a number of prevalent co-morbidities, such as sleep disorders, attention deficit/hyperactivity disorder and epilepsy. No effective treatment for the core symptoms of ASD is currently available. There is increasing interest in cannabinoids, especially cannabidiol (CBD), as monotherapy or add-on treatment for the core symptoms and co-morbidities [...]

Lire la suite

Cannabidiol provides viable treatment opportunity for multiple neurological pathologies of autism spectrum disorder, Bin Gu, 2017

Cannabidiol provides viable treatment opportunity for multipleneurological pathologies of autism spectrum disorder Bin Gu Global Drugs and Therapeutics, Review article, 2017, 2, 6, 1-4 doi: 10.15761/GDT.1000134   Abstract Autism spectrum disorder (ASD)is a heterogeneous neurodevelopmental disorderaffecting over 1% of the general population. While it is well established that ASD stems from a combination of genetic and environmental factors, there are no defined mechanisms of pathogenesis, rendering curative therapy very difficult to establish. No effective therapy exists for ASD, presenting an urgent clinical need for better control of common core pathologies of ASD regardless of its etiology. Cannabidiol (CBD), a major phytocannabinoid constituent of the cannabis plant, is [...]

Lire la suite

Review article : The endocannabinoid system and its therapeutic exploitation in multiple sclerosis : Clues for other neuroinflammatory diseases, Valerio Chiurchiù, 2018

Review article : The endocannabinoid system and its therapeutic exploitation in multiple sclerosis : Clues for other neuroinflammatory diseases Valerio Chiurchiù, Mario van der Stelt, Diego Centonzed, Mauro Maccarrone, Progress in Neurobiology, 2018, 160 , 82–100 © 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).   A B S T R A C T Multiple sclerosis is the most common inflammatory demyelinating disease of the central nervous system, caused by an autoimmune response against myelin that eventually leads to progressive neurodegeneration and disability. Although the knowledge on its underlying neurobiological mechanisms has considerably improved, there is a [...]

Lire la suite

Regulatory Barriers to Research on Cannabis and Cannabinoids : A Proposed Path Forward, Daniele Piomelli et al., 2019

Regulatory Barriers to Research on Cannabis and Cannabinoids : A Proposed Path Forward Daniele Piomelli, Robert Solomon, Donald Abrams, Agnes Balla, Igor Grant, Thomas Marcotte, and John Yoder Cannabis and Cannabinoid Research, Volume 4, Number 1, 2019 Mary Ann Liebert, Inc. DOI: 10.1089/can.2019.0010   After a century of criminalization, the United States and other industrialized countries are experiencing a dramatic shift in their social and legal attitudes toward cannabis. As of January 2019, 10 states (including California) and the District of Columbia have legalized the plant and its products for both medical and adult recreational use, whereas 24 other states have decriminalized its use as medicine.1 [...]

Lire la suite